All lobbying filings

PRIME THERAPEUTICS

PRIME THERAPEUTICS filed a Q1 report for PRIME THERAPEUTICS on April 21, 2025.

Lobbying for PRIME THERAPEUTICS

All filings by PRIME THERAPEUTICS · Everything PRIME THERAPEUTICS has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$420,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Minnesota

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.

Medicare/Medicaid

S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.

Trade (domestic/foreign)

Tariffs on pharmaceuticals.

Bills named in this filing 5

H.R. 2214
DRUG Act
H.R. 10445
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
H.R. 5378
Lower Costs, More Transparency Act
S. 526
Pharmacy Benefit Manager Transparency Act of 2025
S. 891
Bipartisan Health Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.